Skip to main content
logo
Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
3.200
+0.040 (1.27%)
Sep 18, 2026, 4:00 PM EDT - Market closed

Kalaris Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Market Capitalization
76158---
Market Cap Growth
-8.26%----
Enterprise Value
-1682---
Last Close Price
3.208.44---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
PB Ratio
1.322.00---
P/TBV Ratio
1.322.00---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.020.02-0.39--0.61
Net Debt / Equity Ratio
-1.60-1.48-0.365.20-0.04
Net Debt / EBITDA Ratio
-2.53---
Net Debt / FCF Ratio
2.243.02-0.880.22-0.02
Quick Ratio
10.7112.150.070.800.54
Current Ratio
10.9812.230.110.850.69
Return on Equity (ROE)
-79.91%-308.10%---
Return on Assets (ROA)
-31.03%-45.11%-681.04%-232.72%-
Return on Capital Employed (ROCE)
-52.60%-41.20%279.00%2210.80%781.60%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Earnings Yield
-58.11%-27.52%---
FCF Yield
-54.11%-24.44%---
Buyback Yield / Dilution
-235.77%-1042.87%77.99%-36.56%-
SEC Filings: 10-K · 10-Q